Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations
In an interview with CancerNetwork®, Daniel A. Pollyea, MD of the University of Colorado Cancer Center, discussed the rationale behind a study of venetoclax (Venclexta) and azacitidine (Vidaza) for patients with acute myeloid leukemia with IDH mutations.
What this study explores is the particular subset of patients who have IDH mutation[s]. We’ve known from the very beginning of the clinical experience with venetoclax that IDH patients respond even better than the patients who don’t have an IDH mutation. So this study really is the largest look at that, with an opportunity to look at several 100 patients with IDH mutations and what their outcomes were with venetoclax-based regimens, and then look at the placebo group, as well, that didn’t receive venetoclax. So, I think this helps answer a lot of questions that folks have had regarding to what degree this impacts outcomes, and it’s a pretty large degree of response.